CRO.F hVIVO plc

Healthcare Diagnostics & Research Frankfurt Exchange
0.0615 EUR
Close of Nov 11, 2026
0.0440 0.1250
Market cap
EUR 42.3M
P/E
-
P/B
0.95x
ROE
-15.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is CRO.F undervalued?

Graham number

The Graham number of hVIVO plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

hVIVO plc fundamental analysis

No fundamental analysis for hVIVO plc yet.

hVIVO plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About hVIVO plc

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immuno…

Full company profile